Mallinckrodt marks completed spinoff from Covidien

06/30/2013 | St. Louis Post-Dispatch

Mallinckrodt Pharmaceuticals has completed its split from Covidien. CEO Mark Trudeau said the company's strength lies in researching, developing and producing complex products. Mallinckrodt is a major provider of the medical isotope technetium-99m, competing with companies such as GE Healthcare and Bracco Imaging.

View Full Article in:

St. Louis Post-Dispatch

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ